The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Monthly adjustments help maintain financial health by adapting to income shifts, goals, and unexpected expenses with proactive planning.
24,646 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
A high-profile insider sale at Amplitude raises questions for investors. This guide breaks down what amplitude's co-f...
A combo of macro headwinds and a bigger-than-expected debt offering pushed Ciena shares lower. This guide breaks down...
Hearing aid costs top $7,000 for mid-range devices, and Original Medicare offers no coverage. The gap is reshaping se...
Two defense giants, two paths to growth. This guide breaks down Lockheed Martin and RTX, outlining which offers more ...
AI infrastructure relies on powerful chip makers. Here's Taiwan Semiconductor (TSM) emerges as a core holding, combin...
The market buzz around Sweetgreen stock is loud, but hype isn’t a plan. This article weighs momentum against business...
Visa is more than a brand name. This article explores whether could buying visa stock make sense for long-term wealth...
Markets can swing wildly, but your plan shouldn’t. This guide shows how to prepare for a stock market crash coming wi...
A federal betting case involving Malik Beasley and Ed Davis offers timely lessons in money management and self-contro...
When the Fed signals a policy shift, traders rush to position. This article dives into the appeal of a 3X Financial B...
Investors woke to a drop in first majestic silver stock as metal prices wavered and costs rose. This guide breaks dow...